{"id":"23vps","safety":{"commonSideEffects":[{"rate":"20–50%","effect":"Injection site pain, erythema, or swelling"},{"rate":"5–15%","effect":"Fever"},{"rate":"5–10%","effect":"Myalgia or arthralgia"},{"rate":"5–10%","effect":"Headache"},{"rate":"5–10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified capsular polysaccharides from 23 different serotypes of pneumococcus conjugated to a protein carrier or presented as unconjugated polysaccharides. Upon administration, these antigens trigger B-cell and T-cell responses, leading to the production of opsonizing antibodies that enhance phagocytosis and clearance of pneumococcal bacteria. This provides protection against invasive pneumococcal disease and pneumococcal pneumonia caused by the included serotypes.","oneSentence":"23vPS is a 23-valent pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:43:38.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease in adults and children ≥2 years of age"},{"name":"Prevention of pneumococcal pneumonia"}]},"trialDetails":[{"nctId":"NCT00427895","phase":"PHASE3","title":"Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-02-27","conditions":"Pneumococcal Infections","enrollment":2141},{"nctId":"NCT00980655","phase":"PHASE3","title":"Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-01-18","conditions":"Vaccines, Pneumococcal Conjugate Vaccine","enrollment":251},{"nctId":"NCT02124161","phase":"PHASE4","title":"Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-09","conditions":"PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE","enrollment":882},{"nctId":"NCT02079207","phase":"PHASE3","title":"Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2013-12","conditions":"Pneumococcal Infections","enrollment":767},{"nctId":"NCT00962780","phase":"PHASE3","title":"Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-03","conditions":"HIV Infections, Pneumococcal Infections","enrollment":303},{"nctId":"NCT00918580","phase":"PHASE3","title":"Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-11","conditions":"Pneumococcal Conjugate Vaccine","enrollment":158},{"nctId":"NCT01646398","phase":"PHASE3","title":"A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06","conditions":"Pneumococcal Vaccines, Pneumococcal Conjugate Vaccine","enrollment":764},{"nctId":"NCT00963235","phase":"PHASE3","title":"Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-11","conditions":"HIV Infections, Pneumococcal Infections","enrollment":331},{"nctId":"NCT01025336","phase":"PHASE3","title":"Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-12","conditions":"Healthy","enrollment":962},{"nctId":"NCT00500266","phase":"PHASE3","title":"Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-05","conditions":"Pneumococcal Infections","enrollment":1053},{"nctId":"NCT00574548","phase":"PHASE3","title":"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-11","conditions":"Pneumococcal Vaccines","enrollment":720},{"nctId":"NCT00546572","phase":"PHASE3","title":"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-11","conditions":"Pneumococcal Infections","enrollment":938},{"nctId":"NCT00269672","phase":"PHASE2","title":"Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-09","conditions":"Vaccines, Pneumococcal Conjugate Vaccine","enrollment":915}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"23vPS","genericName":"23vPS","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"23vPS is a 23-valent pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in adults and children ≥2 years of age, Prevention of pneumococcal pneumonia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}